TickerFacts.

Novavax Inc (NVAX): Gross Profit

Revenue minus cost of revenue for the same annual period and currency, computed by TickerFacts from the filed figures. The issuer may report gross profit or margin on a different basis.

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

$1.05B
Year ended 2025-12-31
$325.25M
Trailing 12 months to 2026-06-30
-0.9%
3-year compound annual growth
$1.08B2022-12-31: $1.08B2023-12-31: $639.94M2024-12-31: $479.42M2025-12-31: $1.05B$1.05B
2022-12-31 Gross Profit (USD) 2025-12-31
Period endedGross ProfitChange YoYSource filing
2025-12-31$1.05B+119.1%2026-02-26, From 2025-01-01
2024-12-31$479.42M-25.1%2026-02-26, From 2024-01-01
2023-12-31$639.94M-40.7%2026-02-26, From 2023-01-01
2022-12-31$1.08Bn/a2025-02-27, From 2022-01-01

Gross Profit at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedGross ProfitChange YoY
Novavax Inc (NVAX)2025-12-31$1.05B+119.1%
Bio-Techne Corp (TECH)2026-06-30$799.07M+1.1%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$1.17B+36.4%
Repligen Corp (RGEN)2025-12-31$386.25M+40.6%
Moderna, Inc. (MRNA)2025-12-31$1.08B-39.3%
Qiagen N.V. (QGEN)2025-12-31$1.30B+34.3%
ADMA Biologics, Inc. (ADMA)2025-12-31$292.76M+33.3%
Twist Bioscience Corp (TWST)2025-09-30$191.00M+43.2%
Adaptive Biotechnologies Corp (ADPT)2025-12-31$205.62M+92.4%

Compare NVAX, TECH, HALO, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗